Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment
Authors: Simon Birk Kjær Jensen, Victor Sørensen, Rasmus Michael Sandsdal, Eva Winning Lehmann, Julie Rehné Lundgren, Christian Rimer Juhl, Charlotte Janus, Tummas Ternhamar, Bente Merete Stallknecht, Jens Juul Holst, Niklas Rye Jørgensen, Jens-Erik Beck Jensen, Sten Madsbad, Signe Sørensen Torekov
Journal: JAMA Network Open (2024)

Importance A major concern with weight loss is concomitant bone loss. Exercise and glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent weight loss strategies that may protect bone mass despite weight loss. Objective To investigate bone health at clinically relevant sites (hip, spine, and forearm) after diet-induced weight loss followed by a 1-year intervention with exercise, liraglutide, or both combined. Design, Setting, and Participants This study was a predefined secondary analysis of a randomized clinical trial conducted between August 2016 and November 2019 at the University of Copenhagen and Hvidovre Hospital in Denmark. Eligible participants included adults aged 18 to 65 years with obesity (body mass index of 32-43) and without diabetes. Data analysis was conducted from March to April 2023, with additional analysis in February 2024 during revision. Interventions After an 8-week low-calorie diet (800 kcal/day), participants were randomized to 1 of 4 groups for 52 weeks: a moderate- to vigorous-intensity exercise program (exercise alone), 3.0 mg daily of the GLP-1 RA liraglutide (liraglutide alone), the combination, or placebo. Main Outcomes and Measures The primary outcome was change in site-specific bone mineral density (BMD) at the hip, lumbar spine, and distal forearm from before the low-calorie diet to the end of treatment, measured by dual-energy x-ray absorptiometry in the intention-to-treat population. Results In total, 195 participants (mean [SD] age, 42.84 [11.87] years; 124 female [64%] and 71 male [36%]; mean [SD] BMI, 37.00 [2.92]) were randomized, with 48 participants in the exercise group, 49 participants in the liraglutide group, 49 participants in the combination group, and 49 participants in the placebo group. The total estimated mean change in weight losses during the study was 7.03 kg (95% CI, 4.25-9.80 kg) in the placebo group, 11.19 kg (95% CI, 8.40-13.99 kg) in the exercise group, 13.74 kg (95% CI, 11.04-16.44 kg) in the liraglutide group, and 16.88 kg (95% CI, 14.23-19.54 kg) in the combination group. In the combination group, BMD was unchanged compared with the placebo group at the hip (mean change, −0.006 g/cm 2 ; 95% CI, −0.017 to 0.004 g/cm 2 ; P = .24) and lumbar spine (−0.010 g/cm 2 ; 95% CI, −0.025 to 0.005 g/cm 2 ; P = .20). Compared with the exercise group, BMD decreased for the liraglutide group at the hip (mean change, −0.013 g/cm 2 ; 95% CI, −0.024 to −0.001 g/cm 2 ; P = .03) and spine (mean change, −0.016 g/cm 2 ; 95% CI, −0.032 to −0.001 g/cm 2 ; P = .04). Conclusions and Relevance In this randomized clinical trial, the combination of exercise and GLP-1RA (liraglutide) was the most effective weight loss strategy while preserving bone health. Liraglutide treatment alone reduced BMD at clinically relevant sites more than exercise alone despite similar weight loss. Trial Registration EudraCT: 2015-005585-32